Literature DB >> 8263699

Forty-year experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy.

M B Smith1, H Xue, L Strong, H Takahashi, N Jaffe, H Ried, H Zietz, R J Andrassy.   

Abstract

As the cure rate for childhood malignancies increases, the number of patients at risk for development of second malignancies also increases. Due to the potentially long remaining life span, long-term follow-up is difficult and patients are often at risk after presumptive cures. Some authors believe that cure rates for second malignancies are similar to cure rates for primary malignancies. We reviewed the records of 162 patients seen at our institution who had developed a second malignancy after treatment for childhood cancer. Presentation, age at diagnosis, tumor histology, extent of tumor, treatment (including radiotherapy with dosage when available, and chemotherapy) plus outcome were recorded. Mean age at diagnosis of the primary malignancy was 10.3 years. The most common primary malignancy was Hodgkin's disease (33) followed by soft tissue sarcoma (28), retinoblastoma (20), bone tumor (17), central nervous system (CNS) tumor (13), leukemia (8), Wilms' tumor (7), non-Hodgkin's lymphoma (6), neuroblastoma (5), thyroid neoplasm (5), and others (20). The average interval between diagnosis of the first and second malignancy was 10.8 years. These second tumors carried a high mortality. Only 56 patients have no evidence of disease. Five patients are known to be alive with disease and 92 patients have expired due to their second malignancy. Disease status in 8 patients is unknown. The most common second malignancy was osteosarcoma (35) followed by soft tissue sarcoma (24), breast cancer (15), leukemia (14), thyroid carcinoma (14), CNS tumors (12), melanoma (8), nonmelanomatous skin cancer (8), lymphoma (5), and others (27).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8263699     DOI: 10.1016/s0022-3468(05)80325-2

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  11 in total

1.  Coexistence between renal cell cancer and Hodgkin's lymphoma: a rare coincidence.

Authors:  Victor H Jimenez
Journal:  BMC Urol       Date:  2006-03-20       Impact factor: 2.264

2.  Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma.

Authors:  Sara M Federico; Heather B Allewelt; Sheri L Spunt; Melissa M Hudson; Jianrong Wu; Catherine A Billups; Jesse Jenkins; Victor M Santana; Wayne L Furman; Lisa M McGregor
Journal:  J Pediatr Hematol Oncol       Date:  2015-01       Impact factor: 1.289

3.  p53 status in radiation-induced soft-tissue sarcomas.

Authors:  H Taubert; A Meye; M Bache; R Hinze; H J Holzhausen; H Schmidt; F W Rath; J Dunst; P Würl
Journal:  Strahlenther Onkol       Date:  1998-08       Impact factor: 3.621

4.  Medulloblastoma in a patient successfully treated for immature teratoma of the ovary.

Authors:  S Yalçin; N Güler; F Söylemezoğlu
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

5.  Simultaneous occurrence of osteosarcoma and osteochondroma following treatment of neuroblastoma with chemotherapy, radiotherapy, and bone marrow transplantation.

Authors:  M Poustchi-Amin; J C Leonidas; S S Elkowitz
Journal:  Pediatr Radiol       Date:  1996

6.  Inhibition of glioma cell line A-172 MMP activity and cell invasion in vitro by a nutrient mixture.

Authors:  M Waheed Roomi; Vadim Ivanov; Tatiana Kalinovsky; Aleksandra Niedzwiecki; Matthias Rath
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  The role of fragile sites in sporadic papillary thyroid carcinoma.

Authors:  Laura W Dillon; Christine E Lehman; Yuh-Hwa Wang
Journal:  J Thyroid Res       Date:  2012-06-11

8.  Second cancers after childhood cancer--GPs beware!

Authors:  A J Berendsen; A Groot Nibbelink; R Blaauwbroek; M Y Berger; W J E Tissing
Journal:  Scand J Prim Health Care       Date:  2013-08-02       Impact factor: 2.581

9.  Secondary thyroid papillary carcinoma in osteosarcoma patients: report of two cases.

Authors:  Min Suk Kim; Yoon Sang Sim; Soo-Yong Lee; Dae-Geun Jeon
Journal:  J Korean Med Sci       Date:  2008-02       Impact factor: 2.153

10.  DNA topoisomerases participate in fragility of the oncogene RET.

Authors:  Laura W Dillon; Levi C T Pierce; Christine E Lehman; Yuri E Nikiforov; Yuh-Hwa Wang
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.